JP2011500713A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500713A5
JP2011500713A5 JP2010530110A JP2010530110A JP2011500713A5 JP 2011500713 A5 JP2011500713 A5 JP 2011500713A5 JP 2010530110 A JP2010530110 A JP 2010530110A JP 2010530110 A JP2010530110 A JP 2010530110A JP 2011500713 A5 JP2011500713 A5 JP 2011500713A5
Authority
JP
Japan
Prior art keywords
cancer
compound
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500713A (ja
JP5496899B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/080163 external-priority patent/WO2009052287A1/en
Publication of JP2011500713A publication Critical patent/JP2011500713A/ja
Publication of JP2011500713A5 publication Critical patent/JP2011500713A5/ja
Application granted granted Critical
Publication of JP5496899B2 publication Critical patent/JP5496899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530110A 2007-10-16 2008-10-16 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン Active JP5496899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
US60/980,397 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014043175A Division JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Publications (3)

Publication Number Publication Date
JP2011500713A JP2011500713A (ja) 2011-01-06
JP2011500713A5 true JP2011500713A5 (https=) 2011-12-01
JP5496899B2 JP5496899B2 (ja) 2014-05-21

Family

ID=40251685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010530110A Active JP5496899B2 (ja) 2007-10-16 2008-10-16 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン
JP2014043175A Active JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014043175A Active JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Country Status (40)

Country Link
US (4) US8268800B2 (https=)
EP (2) EP2447272B1 (https=)
JP (2) JP5496899B2 (https=)
KR (1) KR101543049B1 (https=)
CN (1) CN101827856B (https=)
AT (1) ATE548374T1 (https=)
BR (1) BRPI0818672B8 (https=)
CA (1) CA2702274C (https=)
CO (1) CO6270330A2 (https=)
CR (1) CR11427A (https=)
CY (3) CY1112781T1 (https=)
DK (1) DK2207786T3 (https=)
EA (1) EA018757B1 (https=)
EC (1) ECSP10010095A (https=)
ES (2) ES2616566T3 (https=)
FI (2) FIC20230040I1 (https=)
FR (2) FR23C1051I2 (https=)
GT (1) GT201000088A (https=)
HR (1) HRP20120419T1 (https=)
HU (2) HUS2300045I1 (https=)
IL (1) IL204732A (https=)
JO (1) JO2778B1 (https=)
LT (2) LTC2207786I2 (https=)
LU (2) LUC00327I2 (https=)
ME (1) ME00997B (https=)
MX (1) MX2010004109A (https=)
MY (1) MY147970A (https=)
NI (1) NI201000055A (https=)
NL (2) NL301256I2 (https=)
NO (2) NO2023048I1 (https=)
NZ (1) NZ584229A (https=)
PL (1) PL2207786T3 (https=)
PT (1) PT2207786E (https=)
RS (1) RS52323B (https=)
SA (1) SA08290661B1 (https=)
SI (1) SI2207786T1 (https=)
TW (1) TWI445539B (https=)
UA (1) UA99476C2 (https=)
WO (1) WO2009052287A1 (https=)
ZA (1) ZA201002178B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP3782612B1 (en) 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
SG194404A1 (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
AU2010234562B2 (en) * 2009-04-06 2016-05-12 Taiho Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
JP5687687B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
RU2681939C2 (ru) 2013-10-29 2019-03-14 Оцука Фармасьютикал Ко., Лтд. Путь синтезирования 2'-дезокси-2'2'-дифтортетрагидроуридинов
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
KR20170042598A (ko) 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
DK3383406T3 (da) * 2015-12-03 2022-01-10 Epidestiny Inc Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
PE20210367A1 (es) 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
WO2020047177A1 (en) * 2018-08-28 2020-03-05 Essenlix Corporation Assay accuracy improvement
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
CN112888700B (zh) * 2018-10-19 2025-03-04 因特欧力多公司 具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
WO2020080912A1 (ko) * 2018-10-19 2020-04-23 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
PH12022550795A1 (en) * 2019-10-08 2023-09-25 Otsuka Pharma Co Ltd 2`-deoxy-2`,2`-difluorotetrahydrouridines with high purity and methods of making the same
PH12022552250A1 (en) * 2020-02-25 2023-11-13 Otsuka Pharma Co Ltd Combination decitabine and cedazuridine solid oral dosage forms
MX2023011120A (es) * 2021-03-26 2023-10-03 Cleveland Clinic Found Tratamiento de la infeccion por virus de arn con un inhibidor de citidina deaminasa.
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
KR20240108406A (ko) 2021-10-19 2024-07-09 아키라바이오, 인크. 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도
US20250127806A1 (en) * 2021-11-01 2025-04-24 St. John's University Injectable liquid pharmaceutical composition containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
CA3266274A1 (en) 2022-08-31 2024-03-07 Taiho Pharmaceutical Co., Ltd. Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0160079B1 (en) 1983-10-26 1990-01-31 GREER, Sheldon B. Method and materials for sensitizing neoplastic tissue to radiation
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
CA2086233C (en) 1991-04-23 1995-10-17 Wendy Oglevee-O'donovan In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
WO1994019362A1 (en) 1993-02-23 1994-09-01 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) * 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
AU5300396A (en) * 1995-03-01 1996-09-18 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
ATE339960T1 (de) * 1999-03-01 2006-10-15 Halogenetics Inc Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
MXPA02002088A (es) 1999-08-26 2003-09-22 Aortech Internat Plc Mejoras en relacion al posicionamiento del cateter.
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
DE60144573D1 (de) 2000-11-29 2011-06-16 Mitsui Chemicals Inc Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
CA2454147C (en) * 2001-07-31 2013-05-21 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Inhibitor of dna methylation
KR20040094692A (ko) 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
WO2006063105A1 (en) 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
AU2010234562B2 (en) 2009-04-06 2016-05-12 Taiho Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
JP5687687B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
UY32546A (es) 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer

Similar Documents

Publication Publication Date Title
JP2011500713A5 (https=)
HRP20120419T1 (hr) Fluoro deoksitetrahidrouridini kao inhibitori citidin deaminaze
JP2014177455A5 (https=)
JP2012522842A5 (https=)
JP2013507439A5 (https=)
JP2009502743A5 (https=)
JP2008528671A5 (https=)
JP2017511311A5 (https=)
JP2011501962A5 (https=)
JP2015500885A5 (https=)
JP2010523670A5 (https=)
JP2014193925A5 (https=)
JP2009515980A5 (https=)
JP2009543802A5 (https=)
JP2015512860A5 (https=)
JP2009536191A5 (https=)
JP2010540556A5 (https=)
JP2017526662A5 (https=)
JP2008536853A5 (https=)
JP2016501838A5 (https=)
JP2012509265A5 (https=)
JP2011518153A5 (https=)
JP2007533742A5 (ja) 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物
JP2011503039A5 (https=)
JP2008528701A5 (https=)